Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice

Diabetes

Volumn 57, Issue 8, 2008, Pages 2118-2127

  Han, Junyan ^a   Zhong, Jinxin ^a   Wei, Wenzhong ^a   Wang, Ying ^a   Huang, Yafei ^a   Yang, Ping ^a   Purohit, Sharad ^a   Dong, Zheng ^a   Wang, Mong Heng ^a   She, Jin Xiong ^a   Gong, Feili ^b   Stern, David M ^c   Wang, Cong Yi ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLUCOSE; GLYCOPROTEIN P 15095; HIGH MOBILITY GROUP B1 PROTEIN; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR FOXP3; ANTIBODY; CD8 ANTIGEN, ALPHA CHAIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; BIOLOGICAL MONITORING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DENDRITIC CELL; DIABETES MELLITUS; DIABETOGENESIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MACROPHAGE ACTIVATION; MEDIATOR; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; SPLEEN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CELL LINE; CELL SURVIVAL; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIGENS, CD11C; ANTIGENS, CD8; AUTOIMMUNITY; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SURVIVAL; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HMGB1 PROTEIN; IMMUNITY, NATURAL; INSULIN-SECRETING CELLS; INTERFERON TYPE II; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50849096898     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1499     Document Type: Article

References (41)

1. Wang CY, Podolsky R, She JX: Genetic and functional evidence supporting SUMO4 as a type 1 diabetes susceptibility gene. Ann N Y Acad Sci 1079:257-267, 2006
2. Wang CY, She JX: SUMO4 and its role in type 1 diabetes pathogenesis. Diabete Metab Res Rev 24:93-102, 2008
3. Li M, Guo D, Isales CM, Eizirik DL, Atkinson M, She JX, Wang CY: SUMO wrestling with type 1 diabetes. J Mol Med 83:504-513, 2005
4. Bach JF, Bendelac A, Brenner MB, Cantor H, De LG, Kronenberg M, Lanier LL, Raulet DH, Shlomchik MJ, von Herrath MG: The role of innate immunity in autoimmunity. J Exp Med 200:1527-1531, 2004
5. Bachmann MF, Kopf M: On the role of the innate immunity in autoimmune disease. J Exp Med 193:F47-F50, 2001
6. Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD: A role for innate immunity in type 1 diabetes? Diabete Metab Res Rev 19:89-100, 2003
7. Carroll M: Innate immunity in the etiopathology of autoimmunity. Nat Immunol 2:1089-1090, 2001
8. Ehl S, Hombach J, Aichele P, Rulicke T, Odermatt B, Hengartner H, Zinkernagel R, Pircher H: Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J Exp Med 187:763-774, 1998
9. Maxwell JR, Campbell JD, Kim CH, Vella AT: CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J Immunol 162:2024-2034, 1999
10. Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P: Lipopoly-saccharide interferes with the induction of peripheral T cell death. Immunity 2:261-270, 1995
11. Fasciano S, Li L: Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products. Curr Med Chem 13:1389-1395, 2006
12. Goldstein DR: Toll-like receptors and other links between innate and acquired alloimmunity. Curr Opin Immunol 16:538-544, 2004
13. Goldstein DR, Palmer SM: Role of Toll-like receptor-driven innate immunity in thoracic organ transplantation. J Heart Lung Transplant 24:1721-1729, 2005
14. Musette P, Auquit Auckbar I, Begon E: [Innate immunity: cutaneous expression of Toll-like receptors]. Med Sci (Paris) 22:149-152, 2006
15. Ruse M, Knaus UG: New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol Res 34:33-48, 2006
16. Ulloa L, Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17:189-201, 2006
17. Bianchi ME, Beltrame M, Paonessa G: Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243:1056-1059, 1989
18. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999
19. Andersson U, Tracey KJ: HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum, Dis Clin North Am 30:627-637, xi, 2004
20. Izuishi K, Tsung A, Jeyabalan G, Critchlow ND, Li J, Tracey KJ, DeMarco RA, Lotze MT, Fink MP, Geller DA, Billiar TR: Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 176:7154-7158, 2006
21. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F: Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 16:794-802, 2007
22. Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, Nyberg F: Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 52:3639-3645, 2005
23. Huang Y, Yin H, Han J, Huang B, Xu J, Zheng F, Tan Z, Fang M, Rui L, Chen D, Wang S, Zheng X, Wang CY, Gong F: Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 7:799 - 808, 2007
24. Mathews CE, Graser RT, Savinov A, Serreze DV, Leiter EH: Unusual resistance of ALR/Lt mouse beta cells to autoimmune destruction: role for beta cell-expressed resistance determinants. Proc Natl Acad SciUSA 98:235-240, 2001
25. Yu G, Fang M, Gong M, Liu L, Zhong J, Feng W, Xiong P, Wang CY, Gong F: Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cells. Transpl Immunol 18:208-219, 2008
26. Xu JF, Huang BJ, Yin H, Xiong P, Feng W, Xu Y, Fang M, Zheng F, Wang CY, Gong FL: A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transpl Int 20:266-276, 2007
27. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, Tracey KJ, Chiorazzi N: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173:307-313, 2004
28. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506-7515, 2005
29. Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, Minev B, Schmidt-Wolf IG, Tracey KJ, Chiorazzi N, Messmer D: Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol 18:1563-1573, 2006
30. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P: The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81:84-91, 2007
31. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D: Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA93:2260-2263, 1996
32. Turley S, Poirot L, Hattori M, Benoist C, Mathis D: Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198:1527-1537, 2003
33. Vasquez AC, Feili-Hariri M, Tan RJ, Morel PA: Qualitative and quantitative abnormalities in splenic dendritic cell populations in NOD mice. Clin Exp Immunol 135:209-218, 2004
34. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195, 2002
35. Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. AmJPhysiol Cell Physiol 291:C1318- C1325, 2006
36. Jiang W, Bell CW, Pisetsky DS: The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J Immunol 178:6495-6503, 2007
37. Saldeen J: Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells. Endocrinology 141:2003-2010, 2000
38. Steinman RM: Some interfaces of dendritic cell biology. APMIS 111:675-697, 2003
39. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM: Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198:235-247, 2003
40. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K, Steinman RM: Dendritic cells are specialized accessory cells along with TGF-{beta} for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3- precursors. Blood 110:4293-4302, 2007
41. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C, Stern A, LaFaille J, Chess L, Stern DM, Jiang H: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9:287-293, 2003